from C.C.Abbot(seeking alpha) «««««At the current valuation ($705M (US) - using an exchange rate of $1 (US)=$1.25CAD), Prometic is valued at only 24% of FibroGen ($2.9B) and 16% of Galapagos ($4.4B), while the potential (soon-to-be-realized) revenue from its pipeline is probably equal to or greater than that of either FibroGen or Galapagos, once profit sharing with their partners is considered.
The very low valuation and higher potential revenue, will in fact make a lot of room for Prometic stock to appreciate. Thus, there exists a tremendous upside, while the downside (the risks) remains similar for each of these three companies as mentioned earlier (i.e. clinical and regulatory).»»»»»
With this extract in mind , the logic of the numbers is in favor of longs !!! You don't create good Cies with shorts , they never created nothing for the society !!!!!